Co-Diagnostics, Inc. (CODX)

NASDAQ: CODX · IEX Real-Time Price · USD
1.18
0.00 (0.00%)
At close: Nov 30, 2023, 4:00 PM
1.15
-0.03 (-2.54%)
After-hours: Nov 30, 2023, 4:50 PM EST
0.00%
Market Cap 36.09M
Revenue (ttm) 4.66M
Net Income (ttm) -42.56M
Shares Out 30.58M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE 16.00
Dividend n/a
Ex-Dividend Date n/a
Volume 50,686
Open 1.14
Previous Close 1.18
Day's Range 1.14 - 1.22
52-Week Range 0.98 - 3.33
Beta -0.53
Analysts Hold
Price Target 3.00 (+154.24%)
Earnings Date Nov 9, 2023

About CODX

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular ... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jul 12, 2017
Employees 145
Stock Exchange NASDAQ
Ticker Symbol CODX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for CODX stock is "Hold" and the 12-month stock price forecast is $3.0.

Price Target
$3.0
(154.24% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023

SALT LAKE CITY , Nov. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o...

1 day ago - PRNewsWire

Co-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

Receives grant award from the Bill & Melinda Gates Foundation in the amount of $9.0M for the development of tuberculosis test on Co-Dx™ PCR platform. SALT LAKE CITY , Nov. 9, 2023 /PRNewswire/ -- Co-D...

21 days ago - PRNewsWire

Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development

Company to use funds awarded by the Bill & Melinda Gates Foundation toward the tuberculosis test for its Co-Dx™ PCR platform SALT LAKE CITY , Nov. 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq:...

4 weeks ago - PRNewsWire

Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for November 2023

SALT LAKE CITY , Oct. 31, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o...

4 weeks ago - PRNewsWire

Co-Diagnostics, Inc. Announces Third Quarter 2023 Earnings Release Date and Webcast

SALT LAKE CITY , Oct. 26, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, ...

5 weeks ago - PRNewsWire

Co-Diagnostics, Inc. to Host Booth at CASMET Symposium October 23-25

SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o...

5 weeks ago - PRNewsWire

Sustainable Infrastructure Dividend ETF Distributions

TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Middlefield Sustainable Infrastructure Dividend ETF (TSX: MINF) (the “Fund”) is pleased to announce that distributions for the fourth quarter of 2023 will be...

5 weeks ago - GlobeNewsWire

Co-Diagnostics, Inc. to Host Booth at Medlab Africa 2023 in Johannesburg, South Africa

SALT LAKE CITY , Oct. 16, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o...

6 weeks ago - PRNewsWire

Co-Diagnostics, Inc. to Participate in the 2023 UHCA/UCAL Fall Convention & Expo on Sept 27-28

SALT LAKE CITY , Sept. 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development ...

2 months ago - PRNewsWire

Co-Diagnostics, Inc. to Participate in 6th ACTC Conference in Skiathos, Greece

SALT LAKE CITY , Sept. 22, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development ...

2 months ago - PRNewsWire

Co-Diagnostics, Inc. to Participate in Gilmartin Group Annual Emerging Growth Showcase on Sept 21

SALT LAKE CITY , Sept. 21, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development ...

2 months ago - PRNewsWire

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023

SALT LAKE CITY, Sept. 7, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of...

3 months ago - PRNewsWire

Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer

SALT LAKE CITY , Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of ...

3 months ago - PRNewsWire

Co-Diagnostics, Inc. to Present at 15th Next Generation Dx Summit in Washington, D.C.

SALT LAKE CITY , Aug. 18, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular...

3 months ago - PRNewsWire

Co-Diagnostics, Inc. to Host Booth at Medlab Asia Conference in Bangkok, Thailand

SALT LAKE CITY , Aug. 16, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o...

3 months ago - PRNewsWire

Co-Diagnostics, Inc. Reports Second Quarter 2023 Financial Results

Co-Dx receives grant awards from the Bill & Melinda Gates Foundation; NIH RADx® Tech to develop tests on our new Co-Dx PCR Home™ platform SALT LAKE CITY , Aug. 10, 2023 /PRNewswire/ -- Co-Diagnostics,...

4 months ago - PRNewsWire

Co-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and Webcast

SALT LAKE CITY , July 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, ...

4 months ago - PRNewsWire

Co-Diagnostics, Inc. to Host Booth and Discuss Recent Grant Awards at AACC 2023 in Anaheim, CA

SALT LAKE CITY , July 20, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m...

4 months ago - PRNewsWire

Co-Diagnostics, Inc. Announces Recent Grant Awards

The Company intends to use funds awarded by the Bill & Melinda Gates Foundation toward completion of tuberculosis and HPV tests for its Co-Dx PCR Home™ platform  SALT LAKE CITY , July 18, 2023 /PRNews...

4 months ago - PRNewsWire

Co-Diagnostics, Inc. Awarded Funding for Co-Dx PCR Home Platform from NIH RADx® Tech Program

The Company intends to use the funds awarded by the National Institutes of Health for completion of its upper respiratory panel multiplex on Co-Dx PCR Home™ platform SALT LAKE CITY , July 13, 2023 /PR...

5 months ago - PRNewsWire

Co-Diagnostics, Inc. Reports First Quarter 2023 Financial Results

Clinical trials for Co-Dx PCR Home™ platform remain on track; Solid cash position and grant funding support long-term strategy SALT LAKE CITY , May 11, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDA...

7 months ago - PRNewsWire

Co-Diagnostics, Inc. to Host Booth at Senior Living Executive Conference in New Orleans, LA

SALT LAKE CITY , May 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of mol...

7 months ago - PRNewsWire

Co-Diagnostics, Inc. Announces First Quarter 2023 Earnings Release Date and Webcast

SALT LAKE CITY , May 5, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, an...

7 months ago - PRNewsWire

Co-Diagnostics, Inc. to Host Booth at 67th Annual CARPHA Conference April 27-29

SALT LAKE CITY , April 26, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...

7 months ago - PRNewsWire

Co-Diagnostics, Inc. to Host Booth at ECCMID 2023 April 15-18 in Copenhagen, Denmark

SALT LAKE CITY , April 13, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...

8 months ago - PRNewsWire